Long-term relapse-free survival in adult acute lymphoblastic leukemia

R. D. Gingrich, C. P. Burns, J. O. Armitage, S. B. Aunan, R. W. Edwards, F. R. Dick, L. C. Maguire, J. T. Leimert

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


An intensive treatment program with curative intent was designed for adults with acute lymphoblastic leukemia (ALL). Forty-eight consecutive patients were treated with this protocol and 39 (81%) obtained a complete remission. Although the complete remission rate was high for patients with both null- and T-cell disease, those with null-cell leukemia had a significantly greater median duration of remission (> 306 weeks) than patients with T-cell disease (62 weeks). The median survival by life-table analysis for the 48 patients is projected to be > 310 weeks, and five patients have finished the 3-year treatment program and have been off therapy for 1-3 years without recurrence of disease. Classification of adult ALL by immune marker status is an important and easily done pretherapy maneuver that identifies subsets of patients with a significantly different prognosis when treated with the protocol described in this study. Those patients for whom leukemic cells had T-cell characteristics had a short median duration of remission. Most importantly, this treatment protocol identifies by therapeutic response a subset of adult patients with ALL whose leukemic blasts are characterized by the absence of immunological markers and who appear, in substantial proportion, to be potentially curable.

Original languageEnglish (US)
Pages (from-to)153-160
Number of pages8
JournalCancer treatment reports
Issue number2
StatePublished - 1985
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Long-term relapse-free survival in adult acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this